Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens
نویسندگان
چکیده
Purpose of the study Fos-Amprenavir is one of the protease inhibitor that is recommended to treat protease inhibitor naïve of experienced patients. Amprenavir and darunavir share at least in part chemical structures and thus a possible selection of close protease gene mutations. Little is known about the frequency and the type of resistance mutations selected after virological failure to FosAmprenavir containing regimen. The aim of this study was to determine the genetic patterns and the prevalence of resistance mutations associated to virological failure to Fos-Amprenavir containing regimens in a cohort of naïve and experienced protease inhibitor patients.
منابع مشابه
Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens
Treatment-emergent mutations and drug resistance were analyzed in virus from HIV-infected children meeting virologic failure (VF) criteria over 48 weeks following treatment with unboosted fosamprenavir or fosamprenavir/ritonavir-containing regimens in studies APV20002 and APV29005. Both antiretroviral therapy (ART)-naïve and ART-experienced patients were enrolled. Patients met VF criteria by ei...
متن کاملPrevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment.
Eleven protease mutations have been associated with reduced susceptibility to darunavir (DRV). We examined the prevalence and covariates of these mutations in 2 populations. Thirty percent of 1175 Northern California patients and 24% of 2744 non-California patients in the Stanford HIV Drug Resistance Database had viruses with 1 or more mutations associated with resistance to DRV. In multivariat...
متن کاملCombating HIV resistance – focus on darunavir
Darunavir is a second-generation protease inhibitor designed to have antiviral efficacy against HIV-1 isolates harboring multiple resistance mutations to protease inhibitors. Pivotal trials conducted in treatment-experienced HIV-infected individuals have demonstrated significantly greater virological suppression when darunavir was added to an optimized background treatment compared with a contr...
متن کاملRole of atazanavir in the treatment of HIV infection
Atazanavir (ATV) is one of the latest protease inhibitors (PI) approved for the treatment of HIV infection. The drug has a relatively long-life (~7 h) and large inhibitory quotient which allows once daily administration. It is generally well tolerated and the main side effect is hyperbilirubinemia, since ATV inhibits the hepatic uridin-glucoronyl-transferase. A signature mutation at the proteas...
متن کاملEffectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
BACKGROUND There are no clinical trials in which the main objective is to compare the efficacy of efavirenz versus ritonavir-boosted protease inhibitor (PI/r)-based initial antiretroviral therapy (ART) in patients with high plasma HIV-1 RNA levels. This study aims to compare these regimens in this patient population in the setting of routine clinical practice. METHODS This was a multicentre, ...
متن کامل